Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348866 | 0.88 | MMP13 (0.51) | MMP13TRPA1EPHX2EGLN1CDK2 | |
| SCHEMBL6477930 | 0.79 | MMP13 (0.48) | MMP13TRPA1EPHX2EGLN1CDK2 | |
| SCHEMBL6194845 | 0.76 | MMP13 (0.48) | MMP13EPHX2NR1H4LMNA | |
| SCHEMBL6191969 | 0.75 | MMP13 (0.48) | MMP13EPHX2NR1H4LMNAMAPT | |
| SCHEMBL6487515 | 0.75 | MMP13 (0.46) | MMP13TRPA1EPHX2EGLN1CDK2 | |
| SCHEMBL6843459 | 0.74 | MMP13 (0.52) | MMP13EPHX2NR1H4 | |
| SCHEMBL6194250 | 0.74 | NR1H4 (0.52) | MMP13EPHX2CDK2GSK3BNR1H4 | |
| SCHEMBL6196444 | 0.72 | MMP13 (0.54) | MMP13EPHX2NR1H4LMNAMAPT | |
| SCHEMBL6698886 | 0.72 | MMP13 (0.51) | MMP13TRPA1EPHX2CDK2GSK3B | |
| SCHEMBL6292169 | 0.72 | MMP13 (0.50) | MMP13CDK2GSK3BNR1H4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 9/4885TRPA1 4097/4885EPHX2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.